Latest U.S. estimates indicate that since 1989, hundreds of thousands of women's lives have been saved by mammography and improvements in breast cancer treatment. The findings point to progress made in early detection and management of breast cancer.
University of Michigan researchers find infiltrating lymphocytes tie to survival in patients with recurrent larynx cancer; findings suggest super-boosting the immune system before additional treatment.
As genetic testing for breast cancer has become more complex, evaluating a panel of multiple genes, it introduces more uncertainty about the results. But a new study finds that newer, more extensive tests are not causing patients to worry more about their cancer risk.
University of Michigan Rogel Cancer Center member Lori Pierce, M.D., was elected president of the American Society of Clinical Oncology.
The University of Michigan research team retrospectively examined 485 women with autologous breast reconstructions (after mastectomies due to breast cancer) who underwent screening mammography over 15 years. The findings suggest that in addition to surveillance, breast cancer patients who undergo mastectomies and autologous tissue reconstruction may benefit from mammography screening of their flaps.
Eric Fearon, M.D., Ph.D., was named a fellow of the American Association for the Advancement of Science, an honor bestowed upon AAAS members by their peers. Fearon is director of the University of Michigan Rogel Cancer Center and Emanuel N. Maisel Professor of Oncology. Several other Rogel Cancer Center members received this honor.
Researchers from the University of Michigan Rogel Cancer Center will attend the American Society of Hematology (ASH) Annual Conference Annual Meeting from Saturday, December 1 through Tuesday, December 4. Many of them plan to participate in poster sessions and oral presentations. A schedule is available to make it easy to know who is presenting, when, where and on what topic.
Liver cancer surveillance among high-risk individuals usually leads to earlier diagnoses and improved survival rates among patients. However, this requires several steps, including identification of high-risk patients, compliance with surveillance recommendations, and highly accurate and accessible imaging tools.
The University of Michigan Rogel Cancer Center has named Andrzej Dlugosz, M.D., associate director for basic science research. He currently co-leads the Rogel Cancer Center’s cancer biology program. In his new role, Dlugosz will oversee the Rogel Cancer Center’s four basic science research programs.
A team at the University of Michigan Rogel Cancer Center recently sought to determine how much newly diagnosed cancer patients understand about the benefits of genetic testing after a diagnosis. Their other objective: to find out whether a decision support tool would help improve that knowledge.